fda glp-1 compounding crackdown october 2025 Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down while @martymakary is photographed holding bootleg # FDA steps up crackdown on

Do you expect the trend to continue and market access to ease more

Semaglutide plans start at $120 per month, and GLP-1/GIP plans start at $235 per month, with all medications compounded by Promise Pharmacy and shipped directly to your home

Riesgo renal (DM2 + enfermedad renal crnica): FLOW (DM2+enfermedad renal crnica) mostr reduccin de afectacin renal y muerte cardiovascular en tratamientos con semaglutida

However, based also on small histopathologic studies that pointed to a marked expansion of the exocrine and endocrine pancreatic compartments with the use of incretin-based therapies, the former being accompanied by increased proliferation and dysplasia and the latter by -cell hyperplasia with the potential for evolution into neuroendocrine tumors [105], concerns remain [106], and monitoring for and reporting of pancreatic adverse effects will continue [104]

doi: 10.1001/jama.2023.14530, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] Raithatha S

The relationship between obesity and bone metabolism is paradoxical, as increased mechanical loading is traditionally associated with higher bone mineral density, yet adiposity-driven chronic inflammation and metabolic dysfunction impair bone quality